Ann: Prescient CEO to step down in early 2025, page-42

My opinion is time for some fresh perspective and fresh experience in the company. SYC has been there 8 years and his ability to attract new investors seemed to be waning.. Despite some good progress with PTX100 the shareprice has been slowly declining. Also I think he has done a great job driving the company to PTX-100 and sharpening the approach to approvals.. Omnicar's issues would have been dissappointing but that is biotech and lets see how they can re-engineer it to address it's shortfall. OmniPryme looks excellent. But SYC put the company on a good path and hasnt been rewarded for it on the Market Cap. I would like to see a different skill in his successor in more the partnering, commercialisation etc skilset to take what SYC started through to hopefully am approved treatment.

Gavin will bring a shareholders perspective to the board and I think will help to improve shareholder communication so we can atract some funds, high net worths to the table. At the moment, Top 20 is 17%. One of the loosest registers I have ever seen. I am hoping to see it tighten up in the next 12 months as we progress. We will need more money before this next trial is finalised and with such a large group of smaller investors which funded the large raise last time, it will be hard to get them to put their hands back in their pockets for more cash if their returns are highly negative from the last round..

My opinion only.